ES2051621A1 - Procedimiento de obtencion de vacuna frente a estafilococos. - Google Patents

Procedimiento de obtencion de vacuna frente a estafilococos.

Info

Publication number
ES2051621A1
ES2051621A1 ES09200223A ES9200223A ES2051621A1 ES 2051621 A1 ES2051621 A1 ES 2051621A1 ES 09200223 A ES09200223 A ES 09200223A ES 9200223 A ES9200223 A ES 9200223A ES 2051621 A1 ES2051621 A1 ES 2051621A1
Authority
ES
Spain
Prior art keywords
vaccine
inoculum
aureus
strain
exopolysaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09200223A
Other languages
English (en)
Other versions
ES2051621B1 (es
Inventor
Zabalza Beatriz Amorena
Domingo Rafael Baselga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Zaragoza
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Zaragoza filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES9200223A priority Critical patent/ES2051621B1/es
Priority to AU34999/93A priority patent/AU3499993A/en
Priority to PCT/ES1993/000007 priority patent/WO1993014784A1/es
Publication of ES2051621A1 publication Critical patent/ES2051621A1/es
Application granted granted Critical
Publication of ES2051621B1 publication Critical patent/ES2051621B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCEDIMIENTO DE OBTENCION DE VACUNA FRENTE A ESTAFILOCOCOS. LA VACUNA ELABORADA ESTA INTEGRADA POR CINCO COMPONENTES: A) BACTERIAS INACTIVADAS DEL GENERO STAPHYLOCOCCUS (S. AUREUS, CEPA 1A Y S. SIMULANS, CEPA C338); B) EXOTOXINAS DE S. AUREUS (CEPA 1A); C) ADYUVANTE DEXTRAN SULFATO; D) EXOPOLISACARIDOS PURIFICADOS DE S. AUREUS (CEPA C104+) Y E) LIPOSOMAS QUE CONTIENEN DICHOS EXOPOLISACARIDOS. ESTA COMPUESTA POR LOS INOCULOS A Y B: LOS COMPONENTES A, B Y C INTEGRAN EL INOCULO A Y LOS COMPONENTES D Y E CONSTITUYEN EL INOCULO B. TODAS LAS CEPAS CONSTITUYENTES FUERON AISLADAS PARA LA VACUNA. LA UTILIZACION DE EXOPOLISACARIDOS PURIFICADOS Y DE LIPOSOMAS PARA INMUNOPOTENCIARLOS (INOCULO B) HACEN A ESTA VACUNA EFICAZ FRENTE A CEPAS MUCHOSAS DE STAPHYLOCOCCUS, MIENTRAS QUE LA APLICACION DEL INOCULO A LA HACEN UTIL FRENTE A CEPAS NO MUCOSAS DE ESTE GENERO, ASI COMO FRENTE A LAS TOXINAS DE S. AUREUS. ESTA VACUNA PUEDE SER APLICADA A ESPECIES DE RUMIANTES (FRENTE A LA MAMITIS) Y TAMBIEN ES SUSCEPTIBLE DE USO EN LA ESPECIE HUMANA.
ES9200223A 1992-02-04 1992-02-04 Procedimiento de obtencion de vacuna frente a estafilococos. Expired - Fee Related ES2051621B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES9200223A ES2051621B1 (es) 1992-02-04 1992-02-04 Procedimiento de obtencion de vacuna frente a estafilococos.
AU34999/93A AU3499993A (en) 1992-02-04 1993-02-04 Vaccine against staphylococci and preparation thereof
PCT/ES1993/000007 WO1993014784A1 (es) 1992-02-04 1993-02-04 Vacuna frente a estafilococos y su elaboracion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9200223A ES2051621B1 (es) 1992-02-04 1992-02-04 Procedimiento de obtencion de vacuna frente a estafilococos.

Publications (2)

Publication Number Publication Date
ES2051621A1 true ES2051621A1 (es) 1994-06-16
ES2051621B1 ES2051621B1 (es) 1995-01-16

Family

ID=8275931

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9200223A Expired - Fee Related ES2051621B1 (es) 1992-02-04 1992-02-04 Procedimiento de obtencion de vacuna frente a estafilococos.

Country Status (3)

Country Link
AU (1) AU3499993A (es)
ES (1) ES2051621B1 (es)
WO (1) WO1993014784A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469132A1 (en) * 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094997A1 (en) * 1981-05-20 1983-11-30 Cornell Research Foundation, Inc. Bovine mastitis vaccine, process for preparing it, and method for detecting efficacy thereof
EP0433242A1 (en) * 1989-10-16 1991-06-19 Fondazione Andrea Cesalpino Vaccines and process for their preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094997A1 (en) * 1981-05-20 1983-11-30 Cornell Research Foundation, Inc. Bovine mastitis vaccine, process for preparing it, and method for detecting efficacy thereof
EP0433242A1 (en) * 1989-10-16 1991-06-19 Fondazione Andrea Cesalpino Vaccines and process for their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RESEARCH IN VETERINARY SCIENCE, Vol. 45, Julio 1988, OXFORD; WATSON, D.L.: "Vaccination against experimental staphylococcal mastitis in ewes", pßg. 16-21 *

Also Published As

Publication number Publication date
AU3499993A (en) 1993-09-01
ES2051621B1 (es) 1995-01-16
WO1993014784A1 (es) 1993-08-05

Similar Documents

Publication Publication Date Title
AU3233795A (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
DE69421939D1 (de) Nichttoxisches schleimhautadjuvans
AU2645988A (en) Mild cleanser and conditioner to yield soft, smooth skin
BR0009166A (pt) Vacina
AU1414899A (en) Surfactant-based antimicrobial compositions and methods for using same
GR3025502T3 (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals.
DE69304521D1 (de) Impfstoff Adjuvans
FI970747A0 (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
AU1798995A (en) Use of extracts of filamentous bacteria as cosmetic agents to combat ageing of the skin
WO2003059246A3 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
HUP0001431A3 (en) An improved peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone lhrh , and analogs of the lhrh tandem repeat peptide and their use as vaccine
DE3574109D1 (en) Vaccine against diseases due to micro-organisms such as mycoplasms, preparation thereof and membranes of micro-organisms as active principle
NO951750D0 (no) Renset "nontypable" Haemophilus influenzae P5 protein som en vaksine for "nontypable" Haemophilus influenzae stamme
ES2051621A1 (es) Procedimiento de obtencion de vacuna frente a estafilococos.
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
DE3686158D1 (de) Impfstoff gegen mastitis.
CA2044721A1 (en) Preparation and use of enzyme-detergent extracted streptococcus zooepidemicus vaccine
CA2037779A1 (en) Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
AU5848690A (en) Preparation for topical treatment of infections caused by virus, bacteria and fungi
ES2082221T3 (es) Neuraminidasa y galactosa-oxidasa en calidad de adyuvante de vacunas.
ES2170377T3 (es) Composicion que contiene quitosana.
AU7728296A (en) Hemoregulatory compounds
AU2396900A (en) Treatment and prevention of hiv and other viral infections

Legal Events

Date Code Title Description
FD2A Announcement of lapse in spain

Effective date: 20141120